SB513: Prescription Monitoring Program; requirements of prescribers of opiates.
Be it enacted by the General Assembly of Virginia:
1. That §§ 54.1-2522.1 and 54.1-2523.2 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-2522.1. Requirements of prescribers.
A. Any prescriber who is licensed in the Commonwealth to treat human patients and is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription for a covered substance shall be registered with the Prescription Monitoring Program by the Department of Health Professions.
B. Prescribers A prescriber registered with the
Prescription Monitoring Program or a person to whom he has delegated
authority to access information in the possession of the Prescription
Monitoring Program pursuant to § 54.1-2523.2 shall, at the time of
initiating a new course of treatment to a human patient that includes the
prescribing of benzodiazepine or an opiate opioids anticipated at
the onset of treatment to last more than 90 14 consecutive days,
request information from the Director for the purpose of determining what, if
any, other covered substances are currently prescribed to the patient. In
addition, any prescriber who holds a special identification number from the
Drug Enforcement Administration authorizing the prescribing of controlled
substances approved for use in opioid addiction therapy shall, prior to or as a
part of execution of a treatment agreement with the patient, request
information from the Director for the purpose of determining what, if any,
other covered substances the patient is currently being prescribed. Nothing in
this section shall prohibit prescribers from making additional periodic
requests for information from the Director as may be required by routine
prescribing practices.
C. The Secretary of Health and Human Resources may identify
and publish a list of benzodiazepines or opiates that have a low potential for
abuse by human patients. Prescribers who prescribe such identified
benzodiazepines or opiates shall not be required to meet the provisions of
subsection B. In addition, a A prescriber shall not be required to
meet the provisions of subsection B if the course of treatment arises from
pain management relating to dialysis or cancer treatments:
1. The opioid is prescribed to a patient currently receiving hospice or palliative care;
2. The opioid is prescribed to a patient as part of treatment for a surgical or invasive procedure and such prescription is not refillable;
3. The opioid is prescribed to a patient during an inpatient hospital admission or at discharge;
4. The opioid is prescribed to a patient in a nursing home or a patient in an assisted living facility that uses a sole source pharmacy;
5. The Prescription Monitoring Program is not operational or available due to temporary technological or electrical failure or natural disaster; or
6. The prescriber is unable to access the Prescription Monitoring Program due to emergency or disaster and documents such circumstances in the patient's medical record.
§ 54.1-2523.2. Authority to access database.
Any prescriber or dispenser authorized to access the
information in the possession of the Prescription Monitoring Program pursuant
to this chapter may, pursuant to regulations promulgated by the Director to
implement the provisions of this section, delegate such authority to health
care professionals individuals who are employed or engaged at the
same facility and under the direct supervision of the prescriber or dispenser
and (i) are licensed, registered, or certified by a health
regulatory board under the Department of Health Professions or in another
jurisdiction and or (ii) employed at the same facility and
under the direct supervision of the prescriber or dispenser have routine
access to confidential patient data and have signed a patient data
confidentiality agreement.
2. That the provisions of this act shall expire on July 1, 2019.
3. That the Director of the Department of Health Professions shall report to the House Committee on Health, Welfare and Institutions and the Senate Committee on Education and Health on utilization of the Prescription Monitoring Program and any impact on prescribing opioids.
Be it enacted by the General Assembly of Virginia:
1. That §§ 54.1-2522.1 and 54.1-2523.2 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-2522.1. Requirements of prescribers.
A. Any prescriber who is licensed in the Commonwealth to treat human patients and is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription for a covered substance shall be registered with the Prescription Monitoring Program by the Department of Health Professions.
B. Prescribers A prescriber registered with the
Prescription Monitoring Program or a person to whom he has delegated
authority to access information in the possession of the Prescription
Monitoring Program pursuant to § 54.1-2523.2 shall, at the time of
initiating a new course of treatment to a human patient that includes the
prescribing of benzodiazepine or an opiate opioids anticipated at
the onset of treatment to last more than 90 14 consecutive days,
request information from the Director for the purpose of determining what, if
any, other covered substances are currently prescribed to the patient. In
addition, any prescriber who holds a special identification number from the
Drug Enforcement Administration authorizing the prescribing of controlled
substances approved for use in opioid addiction therapy shall, prior to or as a
part of execution of a treatment agreement with the patient, request
information from the Director for the purpose of determining what, if any,
other covered substances the patient is currently being prescribed. Nothing in
this section shall prohibit prescribers from making additional periodic
requests for information from the Director as may be required by routine
prescribing practices.
C. The Secretary of Health and Human Resources may identify
and publish a list of benzodiazepines or opiates that have a low potential for
abuse by human patients. Prescribers who prescribe such identified
benzodiazepines or opiates shall not be required to meet the provisions of
subsection B. In addition, a A prescriber shall not be required to
meet the provisions of subsection B if the course of treatment arises from
pain management relating to dialysis or cancer treatments:
1. The opioid is prescribed to a patient currently receiving hospice or palliative care;
2. The opioid is prescribed to a patient as part of treatment for a surgical or invasive procedure and such prescription is not refillable;
3. The opioid is prescribed to a patient during an inpatient hospital admission or at discharge;
4. The opioid is prescribed to a patient in a nursing home or a patient in an assisted living facility that uses a sole source pharmacy;
5. The Prescription Monitoring Program is not operational or available due to temporary technological or electrical failure or natural disaster; or
6. The prescriber is unable to access the Prescription Monitoring Program due to emergency or disaster and documents such circumstances in the patient's medical record.
§ 54.1-2523.2. Authority to access database.
Any prescriber or dispenser authorized to access the
information in the possession of the Prescription Monitoring Program pursuant
to this chapter may, pursuant to regulations promulgated by the Director to
implement the provisions of this section, delegate such authority to health
care professionals individuals who are employed or engaged at the
same facility and under the direct supervision of the prescriber or dispenser
and (i) are licensed, registered, or certified by a health
regulatory board under the Department of Health Professions or in another
jurisdiction and or (ii) employed at the same facility and
under the direct supervision of the prescriber or dispenser have routine
access to confidential patient data and have signed a patient data
confidentiality agreement.
2. That the provisions of this act shall expire on July 1, 2019.
3. That the Director of the Department of Health Professions shall report to the House Committee on Health, Welfare and Institutions and the Senate Committee on Education and Health on utilization of the Prescription Monitoring Program and any impact on prescribing opioids.
Be it enacted by the General Assembly of Virginia:
1. That §§ 54.1-2522.1 and 54.1-2523.2 of the Code of Virginia are amended and reenacted as follows:
§ 54.1-2522.1. Requirements of prescribers.
A. Any prescriber who is licensed in the Commonwealth to treat human patients and is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription for a covered substance shall be registered with the Prescription Monitoring Program by the Department of Health Professions.
B. Prescribers A prescriber registered with the
Prescription Monitoring Program or a person to whom he has delegated
authority to access information in the possession of the Prescription
Monitoring Program pursuant to § 54.1-2523.2 shall, at the time of
initiating a new course of treatment to a human patient that includes the
prescribing of benzodiazepine or an opiate opioids anticipated at
the onset of treatment to last more than 90 14 consecutive days,
request information from the Director for the purpose of determining what, if
any, other covered substances are currently prescribed to the patient. In
addition, any prescriber who holds a special identification number from the
Drug Enforcement Administration authorizing the prescribing of controlled
substances approved for use in opioid addiction therapy shall, prior to or as a
part of execution of a treatment agreement with the patient, request
information from the Director for the purpose of determining what, if any,
other covered substances the patient is currently being prescribed. Nothing in
this section shall prohibit prescribers from making additional periodic
requests for information from the Director as may be required by routine
prescribing practices.
C. The Secretary of Health and Human Resources may identify
and publish a list of benzodiazepines or opiates that have a low potential for
abuse by human patients. Prescribers who prescribe such identified
benzodiazepines or opiates shall not be required to meet the provisions of
subsection B. In addition, a A prescriber shall not be required to
meet the provisions of subsection B if the course of treatment arises from
pain management relating to dialysis or cancer treatments:
1. The opioid is prescribed to a patient currently receiving hospice or palliative care;
2. The opioid is prescribed to a patient as part of treatment for a surgical or invasive procedure and such prescription is not refillable;
3. The opioid is prescribed to a patient during an inpatient hospital admission or at discharge;
4. The opioid is prescribed to a patient in a nursing home or a patient in an assisted living facility that uses a sole source pharmacy;
5. The Prescription Monitoring Program is not operational or available due to temporary technological or electrical failure or natural disaster; or
6. The prescriber is unable to access the Prescription Monitoring Program due to emergency or disaster and documents such circumstances in the patient's medical record.
§ 54.1-2523.2. Authority to access database.
Any prescriber or dispenser authorized to access the
information in the possession of the Prescription Monitoring Program pursuant
to this chapter may, pursuant to regulations promulgated by the Director to
implement the provisions of this section, delegate such authority to health
care professionals individuals who are employed or engaged at the
same facility and under the direct supervision of the prescriber or dispenser
and (i) are licensed, registered, or certified by a health
regulatory board under the Department of Health Professions or in another
jurisdiction and or (ii) employed at the same facility and
under the direct supervision of the prescriber or dispenser have routine
access to confidential patient data and have signed a patient data
confidentiality agreement.
2. That the provisions of this act shall expire on July 1, 2019.
SENATE BILL NO. 513
Be it enacted by the General Assembly of Virginia:
1. That § 54.1-2522.1 of the Code of Virginia is amended and reenacted as follows:
§ 54.1-2522.1. Requirements of prescribers.
A. Any prescriber who is licensed in the Commonwealth to treat human patients and is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription for a covered substance shall be registered with the Prescription Monitoring Program by the Department of Health Professions.
B. Prescribers registered with the Prescription Monitoring
Program shall, at the time of
initiating a new course of treatment to a human patient that includes prior to
the prescribing of benzodiazepine or an opiate
anticipated at the onset of treatment to last more than 90
consecutive days, request information from the Director for
the purpose of determining what, if any, other covered substances are currently
prescribed to the patient. In addition, any prescriber who holds a special
identification number from the Drug Enforcement Administration authorizing the
prescribing of controlled substances approved for use in opioid addiction
therapy shall, prior to or
as a part of execution of a treatment agreement with the patient prescribing such
controlled substances, request information from the
Director for the purpose of determining what, if any, other covered substances
the patient is currently being prescribed. If the
prescribing of benzodiazepine or an opiate continues for more than 90 days
after the date of the initial prescription, the prescriber or his designee
shall request information about the recipient from
the Director in accordance with subsection C 2 of § 54.1-2523 at
least once every 90 days until the course of treatment has ended. Nothing
in this section shall prohibit prescribers from making additional periodic
requests for information from the Director as may be required by routine
prescribing practices.
C. The
Secretary of Health and Human Resources may identify and publish a list of
benzodiazepines or opiates that have a low potential for abuse by human
patients. Prescribers who prescribe such identified benzodiazepines or opiates
shall not be required to meet the provisions of subsection B. In addition, a A
prescriber shall not be required to meet the provisions of subsection B if the course of treatment arises from pain
management relating to dialysis or cancer treatments:
1. The benzodiazepine or opiate is prescribed to a patient currently receiving hospice or palliative care;
2. The benzodiazepine or opiate is prescribed to a patient as part of treatment for a surgical procedure and such prescription is not refillable; or
3. The Prescription Monitoring Program is not operational or available due to temporary technological or electrical failure or natural disaster.
2. That the provisions of this act shall expire on July 1, 2019.